ArticleInvestigational new drugs2008

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Elisabeth I Heath et al.PubMed ↗Publisher ↗

No numbers read from the abstract.